Risperidone,Quetiapine

Kisqali is used to treat certain types of early, advanced, or metastatic HR-positive HER2-negative breast cancer in combination with an endocrine-based agent. It is an oral tablet taken once daily for 21 consecutive days out of a 28-day cycle. Kisqali gained FDA approval on March 13, 2017.

Kisqali is used to treat certain types of early, advanced, or metastatic HR-positive HER2-negative breast cancer in combination with an endocrine-based agent. It is an oral tablet taken once daily for 21 consecutive days out of a 28-day cycle. Kisqali gained FDA approval on March 13, 2017.

Before taking Kisqali, tell your healthcare provider about all of your medical conditions, including if you have: Any heart problems, including heart failure, irregular heartbeats, and QT prolongation Ever had a heart attack A slow heartbeat (bradycardia) High blood pressure that is not controlled Decreased thyroid gland function (hypothyroidism) Problems with the amount of potassium, calcium, phosphorus, or magnesium in your blood A fever, chills, or any other signs or symptoms of infection Liver problems Kidney problems Plans to become pregnant, or are pregnant Plans to breastfeed or are breastfeeding.

No side effects information is recorded for this medicine yet.

Kisqali may cause the following serious side effects. Kisqali may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including: trouble breathing or shortness of breath cough with or without mucus chest pain. Kisqali may cause a skin rash. Tell your healthcare provider or get medical help right away if you get a severe rash; your rash worsens; red skin; flu-like symptoms; skin pain or burning; blistering of the lips, eyes, or mouth; blisters on the skin; or skin peeling, with or without fever. Kisqali can cause a heart problem known as QT prolongation. This condition can cause an abnormal heartbeat and may lead to death. Your healthcare provider should check your heart and do blood tests before and during treatment with Kisqali. Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you feel dizzy or faint. Kisqali can cause serious liver problems. Your healthcare provider should do blood tests to check your liver before and during treatment with Kisqali. Tell your healthcare provider right away if you get any of the following signs and symptoms of liver problems: yellowing of your skin or the whites of your eyes (jaundice) dark or brown (tea-colored) urine feeling very tired loss of appetite pain on the upper right side of your stomach area (abdomen) bleeding or bruising more easily than normal. Low white blood cell counts are very common during treatment with Kisqali and may result in infections that may be severe. Your healthcare provider should check your white blood cell counts before and during treatment with Kisqali. Tell your healthcare provider right away if you have signs and symptoms of low white blood cell counts or infections, such as fever and chills. Kisqali may cause fertility problems in males, which may affect your ability to father a child. Talk to your healthcare provider if this is a problem for you. Your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking Kisqali if you develop certain serious side effects during treatment with Kisqali. Tell your healthcare provider if you have any side effect that bothers you or that do not go away. These are not all of the possible side effects of Kisqali. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Kisqali may cause the following serious side effects. Kisqali may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including: trouble breathing or shortness of breath cough with or without mucus chest pain. Kisqali may cause a skin rash. Tell your healthcare provider or get medical help right away if you get a severe rash; your rash worsens; red skin; flu-like symptoms; skin pain or burning; blistering of the lips, eyes, or mouth; blisters on the skin; or skin peeling, with or without fever. Kisqali can cause a heart problem known as QT prolongation. This condition can cause an abnormal heartbeat and may lead to death. Your healthcare provider should check your heart and do blood tests before and during treatment with Kisqali. Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you feel dizzy or faint. Kisqali can cause serious liver problems. Your healthcare provider should do blood tests to check your liver before and during treatment with Kisqali. Tell your healthcare provider right away if you get any of the following signs and symptoms of liver problems: yellowing of your skin or the whites of your eyes (jaundice) dark or brown (tea-colored) urine feeling very tired loss of appetite pain on the upper right side of your stomach area (abdomen) bleeding or bruising more easily than normal. Low white blood cell counts are very common during treatment with Kisqali and may result in infections that may be severe. Your healthcare provider should check your white blood cell counts before and during treatment with Kisqali. Tell your healthcare provider right away if you have signs and symptoms of low white blood cell counts or infections, such as fever and chills. Kisqali may cause fertility problems in males, which may affect your ability to father a child. Talk to your healthcare provider if this is a problem for you. Your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking Kisqali if you develop certain serious side effects during treatment with Kisqali. Tell your healthcare provider if you have any side effect that bothers you or that do not go away. These are not all of the possible side effects of Kisqali. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

No adult dosage information is recorded for this medicine yet.

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take: CYP3A inhibitors: Avoid concomitant use of Kisqali with strong CYP3A inhibitors, such as clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, verapamil, goldenseal, and grapefruit. If strong inhibitors cannot be avoided, reduce the dose of Kisqali. CYP3A4 inducers , such as phenobarbital, phenytoin, rifampicin, St. John's Wort, and glucocorticoids. Avoid concomitant use. CYP3A substrates , such as midazolam, felodipine, buspirone, lovastatin, eletriptan, sildenafil, simvastatin, triazolam, dexamethasone, antipyrine, quinine: The dose of CYP3A substrates may need to be reduced when given concurrently with Kisqali. QT-prolonging drugs , such as haloperidol, ziprasidone, quetiapine, thioridazine, olanzapine, risperidone, droperidol, amiodarone, sotalol, dofetilide, procainamide, quinidine, flecainide, macrolides, fluoroquinolones. Avoid concomitant use. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine. See the Kisqali Prescribing Information for a full list of interactions.

No storage information is recorded for this medicine yet.